Cite

    Nicolas, J., Hannestad, J., Holden, D., Kervyn, S., Nabulsi, N., Tytgat, D., Huang, Y., Chanteux, H., Staelens, L., Matagne, A., Mathy, F., Mercier, J., Stockis, A., Carson, R. E., & Klitgaard, H. (2016). brivaracetam, a selective high‐affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia, 57, 201–209. http://access.bl.uk/ark:/81055/vdc_100028646472.0x00005e